A first-of-its-kind “master protocol” for a Phase II/III registration trial in lung cancer not only could lead to new treatments for advanced squamous cell disease, it could fundamentally change the clinical development paradigm for new oncologics in the U.S. and elsewhere.
Governmental entities, research and advocacy communities, and the pharmaceutical and device industries have come together through a public-private partnership to create a novel infrastructure for conducting a biomarker-defined, multi-arm, multi-drug registration trial in second-line, non-small cell lung cancer. Details about the master protocol were announced Nov
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?